CureMatch will analyze molecular profiles of US Special Operations Forces cancer patients and produce reports with treatment strategies.

NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

They face a difficult choice, since the treatment may benefit their children but comes with serious risks and unknowns, particularly following reports of patient deaths.

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...